Long-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study Presented by Takeda at American Academy of Neurology Annual Meeting
27 avr. 2023 14h30 HE
|
Ovid Therapeutics Inc.
Interim 2-year findings show soticlestat appeared generally safe and well tolerated, consistent with prior studiesSustained reduction in frequency of drop seizures among Lennox-Gastaut patients and...
Ovid Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference
10 avr. 2023 08h00 HE
|
Ovid Therapeutics Inc.
NEW YORK, April 10, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies...
Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results
13 mars 2023 08h00 HE
|
Ovid Therapeutics Inc.
OV329 Phase 1 trial is progressing on trackAn IV formulation candidate suitable for future clinical trials has been achieved for OV350, one of several compounds from the Company’s KCC2 activator...
Ovid Therapeutics to Present at the 2nd Annual Needham Virtual Neuroscience Forum
09 mars 2023 08h00 HE
|
Ovid Therapeutics Inc.
NEW YORK, March 09, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives...
Studies Published in Cell Reports Medicine Validate the Potential of Direct KCC2 Activation in Resistant Seizures
08 mars 2023 08h00 HE
|
Ovid Therapeutics Inc.
OV350 is the first reported compound that directly binds to and activates the KCC2 co-transporter, a target implicated in neuronal excitation, including epilepsiesTwo preclinical seizure models...
Ovid Therapeutics to Present at the 43rd Annual Cowen Healthcare Conference
28 févr. 2023 08h00 HE
|
Ovid Therapeutics Inc.
NEW YORK, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives...
Ovid Therapeutics Expands Epilepsy Development Expertise with New Appointments
08 févr. 2023 08h00 HE
|
Ovid Therapeutics Inc.
Recognized epileptologist and medical affairs leader, Manoj Malhotra, M.D., joins as Chief Medical Officer Drug discovery and development scientist and soticlestat co-inventor, Toshiya Nishi, D.V.M.,...
Ovid Therapeutics Dosed Healthy Volunteers with OV329 in Phase 1 Trial
05 janv. 2023 08h00 HE
|
Ovid Therapeutics Inc.
NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives...
Ovid Therapeutics to Present Data on Its Epilepsy Programs at American Epilepsy Society Annual Meeting (2022)
02 déc. 2022 10h00 HE
|
Ovid Therapeutics Inc.
Preclinical data demonstrate potential efficacy and safety of OV329 at low, chronic dosing, suggesting an improved profile compared to other GABA-aminotransferase inhibitors Data from the NIH/NINDs...
Ovid Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights
08 nov. 2022 08h00 HE
|
Ovid Therapeutics Inc.
Ovid intends to initiate a Phase 1 study in healthy volunteers in Q4 2022, following the FDA clearance of an Investigational New Drug (IND) application for OV329, its GABA-aminotransferase...